Greenway Medical Technologies Beats on EPS But GAAP Results Lag
Greenway Medical Technologies (NYS: GWAY) reported earnings on May 6. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q3), Greenway Medical Technologies missed slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew slightly. Non-GAAP earnings per share dropped significantly. GAAP earnings per share shrank to a loss.
Margins dropped across the board.
Greenway Medical Technologies reported revenue of $33.8 million. The seven analysts polled by S&P Capital IQ anticipated revenue of $34.3 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.01. The four earnings estimates compiled by S&P Capital IQ predicted -$0.02 per share. Non-GAAP EPS of $0.01 for Q3 were 88% lower than the prior-year quarter's $0.08 per share. GAAP EPS were -$0.02 for Q3 against $0.06 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 49.8%, 510 basis points worse than the prior-year quarter. Operating margin was -8.3%, much worse than the prior-year quarter. Net margin was -1.8%, 600 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $34.5 million. On the bottom line, the average EPS estimate is $0.05.
Next year's average estimate for revenue is $135.0 million. The average EPS estimate is $0.09.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 16 members out of 29 rating the stock outperform, and 13 members rating it underperform. Among seven CAPS All-Star picks (recommendations by the highest-ranked CAPS members), three give Greenway Medical Technologies a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Greenway Medical Technologies is outperform, with an average price target of $17.00.
Is Greenway Medical Technologies the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Greenway Medical Technologies to My Watchlist.
The article Greenway Medical Technologies Beats on EPS But GAAP Results Lag originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.